Secures $1M in Dilutive Private Placement at Discount; Expands Stock Option Pool by 5.5M Shares

summarizeSummary

Brainstorm Cell Therapeutics Inc. secured $1 million in a dilutive private placement at a discount to market price, issuing shares and warrants, and significantly increased its stock option pool by 5.5 million shares.

check_boxKey Events

• Finalizes $1M Private Placement

  The company entered into a Securities Purchase Agreement to raise $1,000,000 through a private placement, with the first closing of $125,000 already completed. This finalizes terms of the financing announced on February 13, 2026.

• Dilutive Offering Terms

  Shares and pre-funded warrants were sold at $0.60 per unit, a discount to the current stock price. Investors also received common stock purchase warrants exercisable for 120% of the purchased shares/pre-funded warrants at a strike price of $1.00.

• Expands Stock Incentive Plan Pool

  The Board approved an amendment to increase the shared pool of shares available for issuance under its 2014 Stock Incentive Plan and 2014 Global Share Option Plan by 5,500,000 shares, resulting in a total pool of 8,406,666 shares for future equity awards.

• Working Capital Use of Proceeds

  Net proceeds from the private placement will be used for general working capital purposes, indicating an ongoing need for operational funding.

auto_awesomeAnalysis

Brainstorm Cell Therapeutics Inc. has finalized a $1 million private placement, previously announced in principle on February 13, 2026. The terms include the sale of common stock and pre-funded warrants at $0.60 per share, a discount to the current market price of $0.6995. Additionally, investors will receive common stock purchase warrants exercisable for 120% of the purchased shares/pre-funded warrants, with an exercise price of $1.00. The financing will occur in up to eight closings, with $125,000 already received and the remaining $875,000 to be funded at the investor's discretion by September 25, 2026. The proceeds are designated for working capital. This highly dilutive capital raise follows a pattern of similar financings, including a $279,000 convertible note issuance in January 2026, highlighting the company's ongoing need for capital. Concurrently, the Board approved a significant increase of 5,500,000 shares to the company's stock incentive plan pool, bringing the total available shares to 8,406,666, which represents substantial potential future dilution for existing shareholders.